The Epidemiology of Breast Implant–Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand Confirms the Highest Risk for Grade 4 Surface Breast Implants

Magnusson, Mark; Beath, Ken; Cooter, Rodney D.; Locke, Marius; Prince, H. Miles; Elder, Elisabeth; Deva, Anand K.

doi:10.1097/prs.0000000000005500

Cited by 122 publications

(96 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has recently been proposed that the material of breast implants may also be an important factor. Magnusson et al report an odds ratio of 23.4 for Silimed polyurethane implants and 16.5 for Biocell implants when compared with Siltex implants as the reference group using data from Australia and New Zealand …”

Section: Resultsmentioning

confidence: 99%

Breast implant–associated anaplastic large cell lymphoma, a systematic review and in‐depth evaluation of the current understanding

Ebner

Liu

Gould

et al. 2019

Journal of Surgical Oncology

View full text Add to dashboard Cite

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a T-cell neoplasm that arises in the capsule around breast implants. While an association with implants has been proposed, no causal link has been identified and the pathophysiology and natural history of BIA-ALCL remain unknown. A literature review of 391 articles was performed to assess the current understanding of BIA-ALCL and to provide a balanced and unbiased view of the current controversy surrounding the disease.

show abstract

Section: Resultsmentioning

confidence: 99%

Breast implant–associated anaplastic large cell lymphoma, a systematic review and in‐depth evaluation of the current understanding

Ebner

Liu

Gould

et al. 2019

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…These diseases are typically ALK negative, are exceptionally rare, and carry a 5-year overall survival (OS) rate of essentially 100%. 10,11 This subtype recently has been classified as a provisional entity in the 2016 classification. Although unusual for a lymphoma, this entity is considered a surgical disease, requiring removal of the implant and a capsulectomy, which is curative, usually with little to no role for systemic chemotherapy.…”

Section: Classification Of the Ptclsmentioning

confidence: 99%

“…New implants do not appear to carry the same risk of ALCL. 11,30 In these patients, controlling the risk factor, such as exposure to HTLV-1, the type of breast implant, and dietary gluten, represent scientifically proven approaches to lower the risk of the TCL. Clearly, from a public health perspective, understanding these associated risk factors and modulating them appropriately represents the best approach to preventing or even managing the disease.…”

Section: Celiac Disease and Eatlmentioning

confidence: 99%

The rapidly changing landscape in mature T‐cell lymphoma (MTCL) biology and management

Marchi

O’Connor

2019

CA A Cancer J Clinicians

View full text Add to dashboard Cite

Historical advances in the care of patients with non-Hodgkin lymphoma (NHL) have been restricted largely to patients with B-cell lymphoma. The peripheral T-cell lymphomas (PTCLs), which are rare and heterogeneous in nature, have yet to experience the same degree of improvement in outcome over the past 20 to 30 years. It is estimated that there are approximately 80,000 and 14,000 cases, respectively, of NHL and Hodgkin lymphoma per year in the United States. As a subgroup of NHL, the PTCLs account for 6% to 10% of all cases of NHL, making them exceedingly rare. In addition, the World Health Organization 2017 classification describes 29 distinct subtypes of PTCL. This intrinsic diversity, coupled with its rarity, has stymied progress in the disease. In addition, most subtypes carry an inferior prognosis compared with their B-cell counterparts, an outcome largely attributed to the fact that most treatment paradigms for patients with PTCL have been derived from B-cell neoplasms, a radically different disease. In fact, the first drug ever approved for patients with PTCL was approved only a decade ago. The plethora of recent drug approvals in PTCL, coupled with a deeper understanding of the molecular pathogenesis of the disease, has stimulated the field to pursue new avenues of research that are now largely predicated on the development of novel, targeted small molecules, which include a host of epigenetic modifiers and biologics. There is an expectation these advances may begin to favorably challenge the chemotherapy paradigms that have been used in the T-cell malignancies.

show abstract

“…15 Recently, Magnusson et al updated the Australiareported risk, noting an odds ratio for developing BIA-ALCL for Biocell (1:3345) implants compared with Siltex (1:86,029) implants of 16.52 (95 percent CI, 3.60 to 293.05; p < 0.0001). 16…”

Section: Epidemiologymentioning

confidence: 99%

Finding Consensus After Two Decades of Breast Implant-Associated Anaplastic Large Cell Lymphoma

Clemens

DeCoster

Fairchild

et al. 2019

Seminars in Plastic Surgery

View full text Add to dashboard Cite

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an emerging and indolent, but potentially fatal cancer of the immune system that can develop around textured-surface breast implants. The World Health Organization first recognized BIA-ALCL as a unique clinical entity in 2016. To date, over 600 confirmed cases have been reported worldwide. BIA-ALCL most commonly presents with disease confined to the capsule, as a seroma or a mass adjacent to the implant. While BIA-ALCL has a fairly indolent clinical course, with an excellent prognosis in early stage disease, disseminated cancer and death have also been reported. In this review, the authors focus on the early diagnosis and treatment, including reconstructing the breast following BIA-ALCL, and also discuss recently updated National Comprehensive Cancer Network guidelines. They also review the current epidemiology and risk factors associated with BIA-ALCL. Finally, they discuss important medicolegal considerations and the bioethics surrounding the continued use of textured-surface breast implants.

show abstract

The Epidemiology of Breast Implant–Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand Confirms the Highest Risk for Grade 4 Surface Breast Implants

Cited by 122 publications

References 31 publications

Breast implant–associated anaplastic large cell lymphoma, a systematic review and in‐depth evaluation of the current understanding

Breast implant–associated anaplastic large cell lymphoma, a systematic review and in‐depth evaluation of the current understanding

The rapidly changing landscape in mature T‐cell lymphoma (MTCL) biology and management

Finding Consensus After Two Decades of Breast Implant-Associated Anaplastic Large Cell Lymphoma

Contact Info

Product

Resources

About